Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of infectious diseases, respiratory diseases and cancer. The company’s novel Toll-like Receptor 9 (TLR9) agonist products are based on its proprietary immunostimulatory sequences (ISS), which are short DNA sequences that stimulate the innate immune response. Dynavax’s clinical product candidates include: HEPLISAV™, a hepatitis B vaccine partnered with Merck & Co., Inc.; a therapy for hepatitis B; and therapies for metastatic colorectal cancer and hepatitis C funded by Symphony Dynamo, Inc. The company’s preclinical pipeline includes an asthma and COPD drug candidate partnered with AstraZeneca and a Universal Flu vaccine.
For more information, visit www.dynavax.com.
Contact Us
Dynavax Technologies
2929 Seventh Street, Suite 100
Berkeley, CA 94710
Phone: 510-848-5100
Fax: 510-848-1379
contact@dynavax.com
Rhein Biotech GmbH
(Dynavax Europe)
Eichsfelder Strasse 11
D-40595 Düsseldorf
Phone: +49-0-211-7-58-45-0
Fax: +49-0-211-7-5-45-130
info@rheinbiotech.de
Investor Relations
Amy Janzen Figueroa
Phone: 510-665-7211
Fax: 510-848-1327
afigueroa@dynavax.com
Transfer Agent
BNY Mellon Shareowner Services
PO Box 358015
Pittsburgh, PA 15252-8015
480 Washington Boulevard
Jersey City, NJ 07310-1900
Telephone:
800-522-6645
Foreign Stockholders:
201-680-6578
TDD for Hearing Impaired:
800-231-5469
TDD for Foreign Stockholders:
201-680-6578
www.bnymellon.com/shareowner/isd